The only two members of FDA’s Cardiovascular and Renal Drugs Advisory Committee to participate in all three reviews of Johnson & Johnson/Bayer HealthCare AG’s Factor Xa inhibitor Xarelto (rivaroxaban) are rotating off the panel.
The membership terms for Mori Krantz, University of Colorado, and Sanjay Kaul, Cedars-Sinai Medical Center, expire June 30. The two...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?